好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Sustained Efficacy Over 1 Year of Treatment With Erenumab: Results From the Extension Phase of the STRIVE Study in Episodic Migraine
Headache
S38 - Headache: Clinical Trials II (1:44 PM-1:55 PM)
005

Erenumab, a fully human monoclonal antibody targeting the canonical CGRP receptor, has demonstrated efficacy and safety in migraine prevention studies.

To assess the long-term efficacy and safety of erenumab over 52 weeks in patients with episodic migraine enrolled in the phase 3 STRIVE study (NCT02456740).

Patients were randomized (1:1:1; n=955) during the 24-week double-blind treatment phase (DBTP) of the STRIVE study to placebo, erenumab 70 mg, or erenumab 140 mg monthly for 24 weeks. At week 24 (active treatment phase [ATP] baseline), 845 patients were rerandomized (1:1) to erenumab 70 mg or 140 mg for the subsequent 28-week dose-blinded ATP. Assessments included monthly migraine days (MMD); monthly acute migraine-specific medication treatment days (MSMD); proportion of patients achieving a ≥50%,  ≥75%, and 100% reduction in MMD (responder rates: RR); and safety.

At week 52, patients receiving erenumab 70 mg (n=421) or 140 mg (n=424) during ATP showed –4.2 / –4.6 MMD changes from study baseline and –1.1/–1.8 MMD from ATP baseline, respectively.  For patients switching from placebo to 70 mg or 140 mg, change from ATP baseline to week 52 in MMD was –2.2 and –2.9, respectively. Improvements were also seen in MSMD. At the end of the study, 61.0% of patients on 70 mg and 64.9% of patients on 140-mg achieved a ≥50% RR; 38.5% of patients on 70 mg and 40.8% of patients on 140 mg achieved a ≥75% RR; 19.8% of patients on 70 mg and 21.2% of patients on 140 mg achieved 100% RR. Safety of erenumab in the ATP was similar to that observed in the DBTP and in prior studies.

Over 52 weeks, erenumab provided sustained efficacy in prevention of episodic migraine and a safety profile comparable to that observed in prior studies, with no new relevant safety findings.

Authors/Disclosures
Denise E. Chou, MD (Pfizer)
PRESENTER
Dr. Chou has received personal compensation for serving as an employee of Pfizer. Dr. Chou has received personal compensation for serving as an employee of Amgen. Dr. Chou has stock in Pfizer. Dr. Chou has stock in Amgen.
Peter Goadsby, MD, PhD, FRS (University of California, Los Angeles) Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli-Lilly. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aurene. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vial. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon Biopharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. The institution of Dr. Goadsby has received research support from Kallyope. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to AAN interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to AAN interests or activities. Dr. Goadsby has a non-compensated relationship as a Executive roles with American Headache Society that is relevant to AAN interests or activities.
Uwe Reuter Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Liily Deutschland. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Allergan. Uwe Reuter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape . Uwe Reuter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for StreaMEdUp. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. The institution of Uwe Reuter has received research support from Novartis.
Yngve Hallstrom No disclosure on file
Gregor Broessner Gregor Broessner has received personal compensation in the range of $0-$499 for serving as a Consultant for Novartis. Gregor Broessner has received personal compensation in the range of $0-$499 for serving as a Consultant for TEVA. Gregor Broessner has received personal compensation in the range of $0-$499 for serving as a Consultant for Lilly. Gregor Broessner has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Gregor Broessner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Gregor Broessner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly.
Jo J. Bonner, MD (Mercy Neurology) No disclosure on file
No disclosure on file
Sandhya Sapra No disclosure on file
Jan Klatt, MD No disclosure on file
Hernan Picard No disclosure on file
Daniel D. Mikol, MD, PhD Dr. Mikol has received personal compensation for serving as an employee of NervGen. Dr. Mikol has received personal compensation for serving as an employee of Amgen. Dr. Mikol has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for NervGen. Dr. Mikol has stock in NervGen. Dr. Mikol has stock in Amgen. Dr. Mikol has received personal compensation in the range of $100,000-$499,999 for serving as a Employee with NervGen.